News | February 15, 2022
Launches and margin sustainability hold key for Glenmark: ICICI Direct
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of Q3FY22 quarter & conference call highlights
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The company has 47 ANDA's pending approval with the U.S.FDA
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Subscribe To Our Newsletter & Stay Updated
